Tech Company Financing Transactions
eTheRNA Funding Round
eTheRNA closed a $38.7 million Series B funding round on 8/24/2022. Investors included Novalis LifeSciences, EQT Life Sciences and Fund+.
Transaction Overview
Company Name
Announced On
8/24/2022
Transaction Type
Venture Equity
Amount
$38,700,000
Round
Series B
Investors
Novalis LifeSciences (Lead Investor) (Marijn Dekkers)
private investors (Kenneth Chien)
Proceeds Purpose
Belgium-based eTheRNA will use the money to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Galileilaan 19
Niel, 2845
Belgium
Niel, 2845
Belgium
Phone
Website
Email Address
Overview
eTheRNA is an mRNA technology platform company with integrated capabilities including mRNA construct design and optimization, coupled with specialized expertise in designing and manufacturing customized lipid nanoparticles (cLNP) formulations tailored for the prevention and treatment of various pathological states, providing end-to-end solutions for next generation mRNA therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bernard Sagaert
Vice President
Stefaan De Koker
VP - Bus. Development
Marina Cools
VP - Bus. Development
Michael Mulqueen
VP - Bus. Development
Dirk Van Broekhoven
VP - Product Management
Phil Challis
Browse more venture capital transactions:
Prev: 8/24/2022: Quivr venture capital transaction
Next: 8/24/2022: Levee Medical venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs